Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Ellis

Showing results (161-170 of 285) with videos related to

Pageof 29
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trialVered Stearns, Judith-Anne W Chapman, Cynthia X Ma, et al.
Cancer|May 3, 2017
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27Allan Lipton, Judith-Anne W Chapman, Kim Leitzel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2010
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancerTorsten O Nielsen, Joel S Parker, Samuel Leung, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 2018
DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancerRyoichi Matsunuma, Doug W Chan, Beom-Jun Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 2, 2009
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancerCarrie R Graveel, Jack D DeGroot, Yanli Su, et al.
Nature Communications|February 27, 2016
RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancerNyam-Osor Chimge, Gillian H Little, Sanjeev K Baniwal, et al.
Cancer Research|April 18, 2023
Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast CancerXuxu Gou, Beom-Jun Kim, Meenakshi Anurag, et al.
Cancer Chemotherapy and Pharmacology|April 17, 2008
Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignanciesPaula M Fracasso, Joel Picus, Jonathan D Wildi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomasHoward A Burris, Herbert I Hurwitz, E Claire Dees, et al.
Transplantation Direct|October 13, 2023
Real-world Experiences in the Transplantation of Hepatitis C-NAAT-positive OrgansJulie M Steinbrink, Jennifer Byrns, Carl Berg, et al.
Pageof 29

Showing results (161-170 of 285) with videos related to

Sort By:
Pageof 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trialVered Stearns, Judith-Anne W Chapman, Cynthia X Ma, et al.
Cancer|May 3, 2017
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27Allan Lipton, Judith-Anne W Chapman, Kim Leitzel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2010
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancerTorsten O Nielsen, Joel S Parker, Samuel Leung, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 2018
DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancerRyoichi Matsunuma, Doug W Chan, Beom-Jun Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 2, 2009
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancerCarrie R Graveel, Jack D DeGroot, Yanli Su, et al.
Nature Communications|February 27, 2016
RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancerNyam-Osor Chimge, Gillian H Little, Sanjeev K Baniwal, et al.
Cancer Research|April 18, 2023
Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast CancerXuxu Gou, Beom-Jun Kim, Meenakshi Anurag, et al.
Cancer Chemotherapy and Pharmacology|April 17, 2008
Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignanciesPaula M Fracasso, Joel Picus, Jonathan D Wildi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomasHoward A Burris, Herbert I Hurwitz, E Claire Dees, et al.
Transplantation Direct|October 13, 2023
Real-world Experiences in the Transplantation of Hepatitis C-NAAT-positive OrgansJulie M Steinbrink, Jennifer Byrns, Carl Berg, et al.
Pageof 29